Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Total Non-Current Liabilities (2020 - 2023)

Historic Total Non-Current Liabilities for Kymera Therapeutics (KYMR) over the last 5 years, with Q4 2024 value amounting to $142.4 million.

  • Kymera Therapeutics' Total Non-Current Liabilities fell 2122.49% to $142.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $142.4 million, marking a year-over-year decrease of 2122.49%. This contributed to the annual value of $142.4 million for FY2024, which is 2122.49% down from last year.
  • Kymera Therapeutics' Total Non-Current Liabilities amounted to $142.4 million in Q4 2024, which was down 2122.49% from $180.8 million recorded in Q4 2023.
  • Over the past 5 years, Kymera Therapeutics' Total Non-Current Liabilities peaked at $203.2 million during Q4 2020, and registered a low of $112.7 million during Q4 2022.
  • Its 5-year average for Total Non-Current Liabilities is $153.5 million, with a median of $149.0 million in 2023.
  • In the last 5 years, Kymera Therapeutics' Total Non-Current Liabilities crashed by 2914.49% in 2022 and then skyrocketed by 6036.55% in 2023.
  • Kymera Therapeutics' Total Non-Current Liabilities (Quarter) stood at $203.2 million in 2020, then fell by 28.05% to $146.2 million in 2021, then fell by 22.89% to $112.7 million in 2022, then surged by 60.37% to $180.8 million in 2023, then decreased by 21.22% to $142.4 million in 2024.
  • Its Total Non-Current Liabilities stands at $142.4 million for Q4 2024, versus $180.8 million for Q4 2023 and $156.8 million for Q3 2023.